This group had a mean MS duration of 21 months before PBMC collection, and even when we divided the RRMS patients based on disease duration, we did not observe any significant effect of CLD exposure on IL-17 levels, indicating that CLD does not influence IL-17-secreting cells irrespective of the stage of MS progression. The gene discussed is IL17A; the disease is myeloid sarcoma.